Browse studies

Find your next paid study

16 recruiting studies matching your filters

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease…

Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more

Estimated

~$10 – $1,125

AstraZenecaNCT06465810

Phase 3

CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition cal…

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Estimated

~$10 – $7,500

Novo Nordisk A/SNCT07207811

Phase 3

TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy (hATTR-PN)

The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality o…

Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN

Estimated

~$10 – $8,750

Alnylam PharmaceuticalsNCT07223203

OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characterist…

ATTR Amyloidosis

Estimated

~$10 – $1,125

AstraZenecaNCT06355934

Patisiran-LNP Pregnancy Surveillance Program

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisi…

Hereditary Transthyretin-mediated (hATTR) AmyloidosisPolyneuropathy

Estimated

~$10 – $1,050

Alnylam PharmaceuticalsNCT05040373

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidos…

Transthyretin-Mediated AmyloidosisATTR Amyloidosis

Estimated

~$10 – $1,050

Alnylam PharmaceuticalsNCT04561518

TAD1 Risk Assessment for Cardiac Amyloidosis With Evuzamitide (TRACE)

The goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA) in patients whose sta…

Amyloidogenic Transthyretin (ATTR) AmyloidosisCardiac Amyloidosis

Estimated

~$10 – $1,125

Lorena SaelicesNCT07538518

Identifying Subclinical Transthyretin Cardiac Amyloidosis in Asymptomatic Carriers of the V122I TTR Allele

Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the tr…

Amyloidosis, HereditaryAmyloidosis CardiacAmyloidosis, Familial+2 more

Estimated

~$10 – $750

University of Texas Southwestern Medical CenterNCT05489549

Phase 3

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated …

Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT07789483

Phase 4

An Open-Label Study to Investigate the Long-Term Effects of Acoramidis on Cardiac Function, Structure and Cardiac Amyloid Burden in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)AmyloidosisAmyloid Cardiomyopathy+1 more

Estimated

~$10 – $8,750

Eidos Therapeutics, a BridgeBio companyNCT07695701

Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): TRACE-AI Prospective Study

The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (…

ATTR Amyloidosis With CardiomyopathyHeart Failure

Estimated

~$10 – $750

Yale UniversityNCT07398950

Iodine-124 Evuzamitide PET/CT Imaging in Carriers of TTR Mutations

The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodi…

ATTRATTR Gene MutationCardiomyopathy+1 more

Estimated

~$10 – $750

University of Texas Southwestern Medical CenterNCT07591038